Sign in
Active, not recruitingNo phase

A Pivotal Study to Evaluate the Clinical Benefit, Performance and Safety of a Totally Implantable Cochlear Implant (TICI) System in Adults

Key facts

Who runs it
Cochlear
Where
Beachwood, Englewood, Iowa City, Kansas City, Miami, New York, Novi, Oklahoma City, Rochester, Salt Lake City, and St Louis, United StatesSee the 11 sites
Trial code
Status
Active, not recruiting
People taking part
56 people, planned
Started
3 Apr 2026
Expected to end
Aug 2028
Type of study
Interventional
Treatments tested
  • Cochlear implant
Record updated
1 October 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 26 criteriaShow less

Who can take part

  • Individuals aged 18 years and older at time of consent
  • Clinically established sensorineural hearing loss (SNHL) defined by a four frequency (500, 1000, 2000, 4000 Hz) pure-tone average unaided threshold (PTA4) of ≥70 dB HL in the ear to be implanted
  • Compromised functional hearing in the aided condition defined as ≤40% correct on a word recognition test in the ear to be implanted
  • Clinically established SNHL defined by a four-frequency (500, 1000, 2000 \& 4000 Hz) pure-tone average unaided threshold (PTA4) of ≥30 dB HL in the contralateral ear
  • Candidate is a fluent speaker in the language used to assess speech perception performance as determined by the investigator
  • Direct access to a compatible Smart Phone
  • Willing and able to provide written informed consent

Who cannot take part

  • Prior cochlear implantation, in either ear, or medical plan for cochlear implantation during the clinical investigation, contralateral to the ear to be implanted
  • Middle ear infection (including acute otitis media, chronic otitis media, suppurative otitis media, or serous drainage) in the ear to be implanted either at the time of surgery or within 3 months prior to enrolment
  • Presence of a tympanic membrane perforation or a history of otologic surgery within 3 months prior to enrolment, in the ear to be implanted
  • Previously reported diagnosis of auditory neuropathy, in the ear to be implanted
  • Severe, or poorer, bilateral sensorineural hearing loss prior to 5 years of age, as reported by the participant
  • Unrealistic expectations on the part of the participant, regarding the possible benefits, risks, and limitations inherent to the surgical procedure(s) and prosthetic devices, as determined by the Investigator
  • Current participation, or participation in another interventional clinical study/trial in the past 30 days, involving an investigational drug or device (unless Cochlear sponsored and determined by Investigator or Sponsor to not impact this investigation)
  • Current cerebrospinal fluid (CSF) shunts or drains, existing perilymph fistula, skull fracture or CSF leaks
  • Medical or psychological conditions that contraindicate general anaesthesia, surgery, or participation in the clinical investigation as determined by the investigator
  • Pre-existing skin condition that could jeopardize wound healing as judged by the investigator e.g., psoriasis, dermatitis, use of corticosteroids, uncontrolled diabetes
  • Candidates with single-sided deafness as determined by the investigator
  • Intra-axial (within-the-brain) lesions or deafness due to lesions of the acoustic nerve affecting the ear to be implanted
  • Ossification, malformation or any other cochlear anomaly, such as common cavity, that might prevent complete insertion of the electrode array, in the ear to be implanted
  • Severe, or poorer, sensorineural hearing loss for more than 20 years, as reported by the participant, in the ear to be implanted
  • Additional disabilities that may affect the participant's participation or safety during the clinical investigation
  • Unable or unwilling to comply with all requirements of the clinical investigation, as determined by the investigator
  • Pregnant or breastfeeding women
  • Investigator site personnel directly affiliated with this study and/or their immediate families. Immediate family is defined as spouse, parent, child or sibling
  • Cochlear employees or employees of Contract Research Organisations or contractors engaged by Cochlear for the purposes of the investigation

Where in United States

  • University Hospitals Cleveland Medical CentreBeachwood, United States
  • Rocky Mountain Ear CenterEnglewood, United States
  • University of IowaIowa City, United States
  • Midwest Ear InstituteKansas City, United States
  • University of Miami School of MedicineMiami, United States
  • NYU Langone HealthNew York, United States
  • Michigan Ear InstituteNovi, United States
  • Hearts for Hearing FoundationOklahoma City, United States
  • Mayo Foundation RochesterRochester, United States
  • University of Utah Hospitals and ClinicsSalt Lake City, United States
  • Washington University School of MedicineSt Louis, United States

About the trial

What the trial wants to find out

This pivotal study examines the clinical efficacy and safety of an investigational totally implantable cochlear implant (TICI) system. The system includes a microphone placed under the skin to detect speech and sound from the environment, providing the option to hear without any visible external parts. This study will involve adults with sensorineural hearing loss, a type of hearing loss caused by damage to the inner ear or auditory nerve (the nerve that carries sound signals from the ear to the brain). Participants will complete hearing tests and questionnaires to evaluate how well the system works and how it affects their daily life.

The group in the trial

  • Totally Implantable Cochlear Implant SystemTreatment being tested

    Participants will be implanted with the TI1132 implant

    Treatment: Cochlear implant

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Pivotal, Pre-market, Prospective, Interventional, Multi-centre Study to Evaluate Clinical Benefit, Performance, and Safety of the TI1132 Implant in an Adult Population With Sensorineural Hearing Loss
Record updated
1 October 2026